# reload+after+2024-01-23 19:46:44.649229
address1§6 Tide Street
address2§Suite 400
city§Boston
state§MA
zip§02210
country§United States
phone§617 482 2333
fax§617 482 3337
website§https://www.puretechhealth.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§PureTech Health plc, a clinical stage biotherapeutics company, engages in the discovery, development, and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, currently under Phase 3 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, to inhibit the activity of galectin-9 for treating solid tumors and hematological malignancies. It is also developing LYT-300, an oral allopregnanolone, currently completed Phase 1 stage, to treat depression, anxiety, and related indications; and LYT-310, an oral cannabidiol, currently under preclinical stage, to treat epilepsies and other neurological indications. In addition, the company is developing LYT-503/IMB-150, a non-opioid inflammation targeted disease immunomodulation for the potential treatment of interstitial cystitis, or bladder pain syndrome; and Glyph technology platform, a lymphatic-targeting chemistry platform, which leverages the body's natural lipid absorption and transports the process to orally administer drugs via the lymphatic system. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.
fullTimeEmployees§111
companyOfficers§[{'maxAge': 1, 'name': 'Ms. Daphne  Zohar', 'age': 52, 'title': 'Founder, CEO & Executive Director', 'yearBorn': 1971, 'fiscalYear': 2022, 'totalPay': 1006052, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Bharatt M. Chowrira J.D., Ph.D.', 'age': 58, 'title': 'President, Secretary, Chief Business Finance & Operating Officer and Executive Director', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 800551, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Robert S. Langer Jr., Ph.D.', 'age': 74, 'title': 'Co-Founder & Non-Executive Director', 'yearBorn': 1949, 'fiscalYear': 2022, 'totalPay': 145000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David R. Elmaleh Ph.D.', 'age': 75, 'title': 'Co-Founder & Senior Advisor', 'yearBorn': 1948, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Allison Mead Talbot', 'title': 'Head of Communications & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Spencer  Ball', 'title': 'Senior Vice President of Human Resources', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Eric  Elenko Ph.D.', 'age': 50, 'title': 'Chief Innovation & Strategy Officer', 'yearBorn': 1973, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Aleksandra  Filipovic M.D., Ph.D.', 'title': 'Head of Oncology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Cheryl  Murphy Ph.D.', 'title': 'Head of Grants Management & Strategy', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Anita  Terpstra J.D., Ph.D.', 'title': 'Senior VP & Head of Intellectual Property', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§10
boardRisk§3
compensationRisk§10
shareHolderRightsRisk§1
overallRisk§9
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.914
priceToSalesTrailing12Months§61.544624
currency§USD
dateShortInterest§1702598400
exchange§NGM
quoteType§EQUITY
shortName§PureTech Health plc
longName§PureTech Health plc
firstTradeDateEpochUtc§1605537000
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§b3befbc5-de9a-359f-ae02-9ade770a8642
gmtOffSetMilliseconds§-18000000
targetHighPrice§58.0
targetLowPrice§58.0
targetMeanPrice§58.0
targetMedianPrice§58.0
recommendationMean§1.0
recommendationKey§strong_buy
numberOfAnalystOpinions§1
quickRatio§7.162
grossMargins§3.6781101
ebitdaMargins§0.0
trailingPegRatio§None
